Detalhe da pesquisa
1.
Adaptive designs in dermatology clinical trials: Current status and future perspectives.
J Eur Acad Dermatol Venereol
; 2024 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38619384
2.
Tapinarof for psoriasis and atopic dermatitis: 15 years of clinical research.
J Eur Acad Dermatol Venereol
; 37(6): 1168-1174, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-36708084
3.
Estimands for atopic dermatitis clinical trials: Expert opinion on the importance of intercurrent events.
J Eur Acad Dermatol Venereol
; 37(5): 976-983, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-36652273
4.
Sensitivity of clinician-assessed efficacy outcome measurement instruments in trials of topical therapies for atopic dermatitis: a systematic review and meta-analysis.
J Eur Acad Dermatol Venereol
; 36(2): 196-212, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34661930
5.
Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials.
J Eur Acad Dermatol Venereol
; 35(2): 476-485, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-32926462
6.
Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials.
Br J Dermatol
; 183(2): 242-255, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31995838
7.
Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate-to-severe plaque psoriasis: results from a randomized phase II study.
Br J Dermatol
; 181(1): 88-95, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30734266
8.
The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study.
Br J Dermatol
; 181(4): 733-742, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30919407
9.
Harmonizing body surface area assessments between the Eczema Area and Severity Index, SCORing Atopic Dermatitis, and handprint methods utilizing one shared measurement-A proposal to improve efficiency and reduce error in atopic dermatitis trials.
J Eur Acad Dermatol Venereol
; 2024 Feb 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38385652
10.
Optimization of placebo use in clinical trials with systemic treatments for atopic dermatitis: an International Eczema Council survey-based position statement.
J Eur Acad Dermatol Venereol
; 33(5): 807-815, 2019 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-30859656
11.
Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study.
Br J Dermatol
; 179(4): 853-862, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29782642
12.
Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis.
Br J Dermatol
; 179(4): 844-852, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29747232
13.
A phase 2a randomized controlled study to evaluate the pharmacokinetic, safety, tolerability and clinical effect of topically applied Umeclidinium in subjects with primary axillary hyperhidrosis.
J Eur Acad Dermatol Venereol
; 32(1): 145-151, 2018 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-29055158
14.
Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study).
J Eur Acad Dermatol Venereol
; 32(9): 1507-1514, 2018 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-29444376
15.
Apremilast for the treatment of moderate-to-severe palmoplantar psoriasis: results from a double-blind, placebo-controlled, randomized study.
J Eur Acad Dermatol Venereol
; 32(3): 403-410, 2018 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-29055155
16.
Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study.
Br J Dermatol
; 177(4): 1033-1042, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-28580579
17.
Adapalene 0.1%/benzoyl peroxide 2.5% gel reduces the risk of atrophic scar formation in moderate inflammatory acne: a split-face randomized controlled trial.
J Eur Acad Dermatol Venereol
; 31(4): 737-742, 2017 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-27790756
18.
Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial.
Br J Dermatol
; 175(5): 902-911, 2016 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-27423107
19.
Identification of key research needs for topical therapy treatment of psoriasis - a consensus paper by the International Psoriasis Council.
J Eur Acad Dermatol Venereol
; 30(7): 1115-9, 2016 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-26969587
20.
Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE).
Br J Dermatol
; 173(3): 777-87, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25823958